Je was op zoek naar: polymorphism (Engels - Sloveens)

polymorphism
polimorfizem (kristalografija)

cyp2d6 polymorphism
polimorfizem cyp2d6

cyp2c9 polymorphism:
polimorfizem cyp2c9:

restriction fragment length polymorphism
polimorfizem dolžine restrikcijskega fragmenta

this enzyme exhibits genetic polymorphism.
ta encim kaže genetski polimorfizem.

this is an example of intrapopulational polymorphism.
santiago bernabéu je nogometni stadion v madridu.

there is a genetic polymorphism of this enzyme.
ta encim kaže genetski polimorfizem.

both ugt1a9 and ugt2b4 are subject to genetic polymorphism.
ugt1a9 in ugt2b4 sta podvržena genetskemu polimorfizmu.

hcv geno/subtype and presence of q80k polymorphism in hcv genotype 1a
hcv geno/podtip in prisotnost polimorfizma q80k hcv genotipa 1a

hcv geno/subtype and presence of baseline q80k polymorphism in hcv genotype 1a
hcv geno/podtip in prisotnost polimorfizma q80k ob izhodišču pri hcv genotipa 1

immune responses to the vaccine have not been studied in the context of genetic polymorphism.
imunskih odzivov na cepivo v okviru genetskih polimorfizmov niso preučevali.

the expression of cyp3a and cyp3a4 may vary by as much as 40 fold due to genetic polymorphism.
zaradi genetskega polimorfizma se izražanje cyp3a in cyp3a4 lahko razlikuje tudi do 40-krat.

dose adjustment is not considered necessary in subjects with reduced ugt1a1 activity due to genetic polymorphism.
pri osebah z zmanjšano aktivnostjo ugt1a1 zaradi genetskega polimorfizma odmerka ni treba prilagajati.

studies in japanese patients have suggested an effect of cyp2a6*4 polymorphism on teysuno pharmacokinetics.
iz študij z japonskimi bolniki izhaja, da polimorfizem cyp2a6*4 vpliva na farmakokinetične lastnosti zdravila teysuno.

alternative therapy should be considered for patients infected with hcv genotype 1a with the q80k polymorphism or in cases where testing is not accessible.
pri bolnikih, okuženih s hcv genotipa 1a in s polimorfizmom q80k in v primerih kjer testiranje ni možno, je treba razmisliti o alternativnem zdravljenju.

a study in cyp2d6 poor metabolisers showed no evidence of a clinically significant effect of cyp2d6 genetic polymorphism on systemic exposure to umeclidinium bromide.
Študija slabih metabolizatorjev s cyp2d6 ni pokazala klinično pomembnega vpliva genetskega polimorfizma cyp2d6 na sistemsko izpostavljenost umeklidinijevemu bromidu.

cyp2d6 genetic polymorphism has minimal impact on the mean plasma exposure to mirabegron (see section 5.2).
genetski polimorfizem cyp2d6 ima minimalni vpliv na povprečno plazemsko izpostavljenost mirabegronu (glejte poglavje 5.2).

pcr products amplified from r. solanacearum dna produce a distinctive restriction fragment length polymorphism with enzyme ava ii after incubation at 37 °c.
produkti pcr, pomnoženi iz dnk bakterije r. solanacearum, proizvedejo značilen polimorfizem dolžin restrikcijskih fragmentov z encimom ava ii po inkubaciji pri 37 °c.

cytochrome p450 cyp2c9 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity, such as those homozygous for the cyp2c9*3 polymorphism.
aktivnost citokroma p450 cyp 2c9 je manjša pri posameznikih z genetskim polimorfizmom, ki zmanjšuje aktivnost encima, npr. pri tistih s homozigotnostjo za polimorfizem cyp2c9*3.

pazopanib may have a greater impact on sn- 38 disposition in subjects with the ugt1a1*28 polymorphism relative to subjects with the wild-type allele.
pazopanib pri osebah s polimorfizmom ugt1a1*28 morda bolj vpliva na odstranjevanje sn-38 kot pri osebah z divjim tipom alela.